Glenmark Pharmaceuticals

1,400.20
-2.90
(-0.21%)
Market Cap
39,511.99 Cr
EPS
-53.22
PE Ratio
-
Dividend Yield
0.18 %
Industry
Healthcare
52 Week High
1,830.95
52 Week low
883.00
PB Ratio
4.68
Debt to Equity
0.34
Add Ratio

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from10 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy50.00 %
50.00 %
Hold40.00 %
40.00 %
Sell10.00 %
10.00 %

Company News

View All News
Caret
positive
Glenmark Pharmaceuticals Ltd: Launches OTC Laxative to Rival MiraLAX1 day ago
Glenmark Therapeutics Inc., USA has launched Polyethylene Glycol 3350, Powder for Solution, an over-the-counter laxative competing with Bayer's MiraLAX. The product enters a market with annual sales of approximately $555.7 million. Glenmark's shares were trading at ₹1,399.35, down 0.36% on the NSE.
positive
Glenmark Therapeutics Launches OTC Polyethylene Glycol Solution in USA1 day ago
Glenmark Therapeutics Inc., USA, a subsidiary of Glenmark Pharma, has launched an over-the-counter Polyethylene Glycol 3350 powder solution. The product comes in 17 grams per capful dosage. This solution has achieved significant market success, with annual sales reaching approximately $555 million.
Competitors LTP Market Cap (₹ Cr.) P/E Ratio Revenue (₹ Cr.) YoY Revenue Growth % Net Profit (₹ Cr.) YoY Profit Growth % RSI
1,655.30 3,97,161.92 32.77 49,887.20 12.06 9,648 13.77 47.46
5,546.25 1,47,235.51 70.79 8,184.00 0.89 1,600 64.53 40.99
1,445.75 1,16,760.80 23.67 26,520.70 14.17 4,155 47.38 48.78
3,057.95 1,03,494.92 55.81 10,785.70 11.59 1,656 13.54 47.28
1,116.65 93,174.49 17.40 28,905.40 12.36 5,578 1.69 31.30
2,210.20 91,185.54 45.68 10,615.60 19.57 1,942 -16.38 33.38
899.85 90,545.97 19.82 19,831.50 13.82 3,831 29.92 45.15
1,976.10 90,149.20 31.98 20,141.50 19.94 1,936 38.82 44.40
30,496.50 64,802.93 48.79 6,097.20 10.80 1,201 16.01 58.42
1,090.65 63,345.13 18.00 29,559.20 17.55 3,169 -10.04 42.48
Growth Rate
Revenue Growth
6.58 %
Net Income Growth
1,943.30 %
Cash Flow Change
-142.44 %
ROE
2,463.74 %
ROCE
56.66 %
EBITDA Margin (Avg.)
-0.74 %

Quarterly Financial Results

Quarterly Financials
Mar 2015
Jun 2015
Sept 2015
Dec 2015
Mar 2016
Jun 2016
Sept 2016
Dec 2016
Mar 2017
Jun 2017
Sept 2017
Dec 2017
Mar 2018
Jun 2018
Sept 2018
Dec 2018
Mar 2019
Jun 2019
Sept 2019
Dec 2019
Mar 2020
Jun 2020
Sept 2020
Dec 2020
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Revenue
1,754
1,631
1,880
1,749
2,211
1,986
2,171
2,478
2,373
2,345
2,253
2,148
2,317
2,268
2,847
2,401
2,565
2,285
2,845
2,672
2,788
2,396
2,879
2,787
2,838
3,005
3,112
3,155
3,068
2,903
3,069
3,272
3,062
3,018
3,281
2,625
3,814
3,255
3,440
3,333
Expenses
1,682
1,288
1,506
1,408
2,003
1,590
1,775
1,770
2,094
1,786
1,868
1,881
1,953
1,819
2,141
2,120
2,199
1,981
2,365
2,296
2,302
1,867
2,400
2,257
2,337
2,391
2,557
2,659
2,638
2,346
2,539
2,626
3,402
2,651
3,071
2,792
3,005
2,656
2,832
2,787
EBITDA
73
343
374
341
208
395
396
708
279
559
385
267
365
449
706
280
366
304
480
376
487
529
480
531
502
614
555
497
430
558
530
646
-340
367
211
-168
808
599
608
546
Operating Profit %
4 %
21 %
20 %
19 %
9 %
17 %
18 %
28 %
14 %
23 %
16 %
13 %
13 %
15 %
16 %
16 %
13 %
13 %
14 %
13 %
15 %
19 %
17 %
18 %
17 %
19 %
18 %
15 %
11 %
14 %
15 %
14 %
-15 %
12 %
3 %
-13 %
0 %
18 %
17 %
16 %
Depreciation
65
65
59
52
58
64
69
63
69
78
75
75
74
79
82
83
81
91
94
106
126
113
104
115
111
113
123
119
132
147
146
152
135
142
141
147
151
118
120
123
Interest
40
42
43
47
48
43
63
62
70
71
70
71
74
79
85
89
82
93
90
96
99
94
81
95
83
76
69
67
87
60
83
97
109
112
122
134
149
40
49
52
Profit Before Tax
-10
257
303
274
209
348
315
655
173
444
273
154
249
327
580
154
240
160
347
271
318
358
339
348
338
444
385
343
270
408
337
435
-542
151
-6
-403
555
462
473
456
Tax
-20
75
87
78
60
121
92
178
-11
111
59
49
97
94
166
38
79
51
92
80
98
104
105
100
104
137
110
103
97
197
58
144
-139
-22
56
-72
1,770
122
118
108
Net Profit
11
183
216
196
149
227
224
477
184
333
214
105
152
233
414
116
162
109
256
191
220
254
234
248
234
307
275
240
173
211
279
291
-403
173
-62
-331
-1,214
340
355
348
EPS in ₹
0.39
6.66
7.66
6.95
5.28
8.04
7.92
16.91
6.51
11.81
7.59
3.71
5.37
8.26
14.67
4.12
5.73
3.87
9.06
6.76
7.81
9.00
8.29
8.80
8.29
10.86
9.13
7.86
5.51
6.82
9.23
9.66
-15.18
5.31
-2.90
-12.45
-43.17
12.06
12.55
12.33

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total Assets
9,688
10,193
11,764
12,595
13,296
14,685
15,604
17,083
19,372
14,359
Fixed Assets
2,836
2,594
2,755
3,030
3,670
5,029
5,129
5,887
5,422
4,210
Current Assets
5,323
5,904
6,875
6,989
6,697
6,804
7,360
8,282
10,726
7,428
Capital Work in Progress
492
543
708
1,122
1,399
1,222
1,382
1,010
1,190
662
Investments
0
17
16
15
30
25
25
50
45
790
Other Assets
6,359
7,039
8,285
8,429
8,197
8,410
9,068
10,137
12,716
8,697
Total Liabilities
9,688
10,193
11,764
12,595
13,296
14,685
15,604
17,083
19,372
14,359
Current Liabilities
3,711
3,999
2,703
3,288
4,021
4,126
4,201
4,689
5,105
5,819
Non Current Liabilities
2,976
2,564
4,569
4,144
3,670
4,489
4,338
2,956
4,427
693
Total Equity
3,000
3,629
4,492
5,163
5,605
6,070
7,064
9,438
9,839
7,848
Reserve & Surplus
2,973
3,601
4,464
5,135
5,577
6,042
7,036
9,058
9,446
7,820
Share Capital
27
28
28
28
28
28
28
28
28
28

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-31
93
199
177
-297
174
28
272
33
215
Investing Activities
-712
-950
-1,001
-1,003
-883
-774
-662
-316
-515
4,387
Operating Activities
482
345
657
1,648
1,324
1,392
1,131
1,109
625
-265
Financing Activities
199
699
543
-469
-739
-445
-442
-521
-78
-3,906

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Promoter
46.63 %
46.63 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.65 %
46.64 %
46.65 %
46.65 %
46.65 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
24.80 %
23.71 %
21.38 %
20.98 %
23.05 %
23.51 %
DIIs
3.82 %
4.94 %
5.09 %
7.08 %
6.62 %
6.01 %
10.64 %
10.69 %
10.41 %
9.11 %
10.32 %
10.92 %
13.36 %
13.92 %
13.21 %
13.85 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
0.04 %
Public / Retail
15.92 %
14.43 %
16.02 %
15.88 %
15.88 %
16.32 %
16.47 %
16.72 %
16.90 %
15.20 %
14.83 %
14.77 %
14.83 %
14.58 %
13.61 %
12.65 %
Others
33.63 %
34.00 %
32.25 %
30.40 %
30.86 %
31.02 %
26.21 %
25.91 %
26.01 %
29.01 %
3.37 %
3.92 %
3.75 %
3.83 %
3.45 %
3.31 %
No of Share Holders
2,50,849
2,75,801
3,29,870
3,17,383
3,10,516
3,12,473
3,13,540
3,00,106
2,85,461
2,36,908
2,32,685
2,09,931
1,99,451
1,92,630
1,93,949
1,95,059

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 2 2 2 2.5 2.5 2.5 2.5 2.5 0.00
Dividend Yield (%) 0.00 0.38 0.31 0.97 0.54 0.57 0.56 0.26 0.18 0.00

Corporate Action

Announcements

Announcement under Regulation 30 (LODR)-Press Release / Media Release
1 day ago
Announcement under Regulation 30 (LODR)-Press Release / Media Release
8 days ago
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Feb 27, 2025, 16:30
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Feb 27, 2025, 16:30
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Feb 27, 2025, 08:58
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Feb 27, 2025, 08:58
Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosures Requirements) Regulations 2015: Glenmark Pharmaceuticals Ltd. (Hereinafter Referred As The Company)
Feb 24, 2025, 09:58
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Feb 19, 2025, 17:01
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Feb 17, 2025, 16:24
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Feb 17, 2025, 12:17
Integrated Filing (Financial)
Feb 14, 2025, 19:57
U.S. FDA Inspection At The Companys Facility At Indore Madhya Pradesh India
Feb 14, 2025, 19:30
Announcement under Regulation 30 (LODR)-Change in Directorate
Feb 14, 2025, 19:15
Announcement under Regulation 30 (LODR)-Investor Presentation
Feb 14, 2025, 19:04
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Feb 14, 2025, 18:59
Board Meeting Outcome for Unaudited Financial Results (Standalone And Consolidated) For The Third Quarter And Nine Months Ended 31St December 2024
Feb 14, 2025, 18:19
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Feb 14, 2025, 08:50
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Feb 12, 2025, 09:06
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Feb 10, 2025, 11:25
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Feb 08, 2025, 15:05
Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
Feb 07, 2025, 22:06
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Feb 05, 2025, 13:31
Closure of Trading Window
Feb 03, 2025, 16:31
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Third Quarter And Nine Months Ended December 31 2024.
Feb 03, 2025, 16:25
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Jan 21, 2025, 08:48
Intimation Of Change In The Name Of The Step Down Wholly Owned Subsidiaries Of The Company.
Jan 08, 2025, 17:12
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dec 16, 2024, 08:49
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dec 10, 2024, 06:55
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Nov 27, 2024, 18:18
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Nov 27, 2024, 08:52
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Nov 21, 2024, 17:19
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Nov 18, 2024, 15:57
Announcement under Regulation 30 (LODR)-Investor Presentation
Nov 14, 2024, 19:47
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Nov 14, 2024, 18:54
Board Meeting Outcome for Unaudited Financial Results (Standalone And Consolidated) For The Second Quarter And Half Year Ended 30Th September, 2024
Nov 14, 2024, 18:37
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Nov 06, 2024, 17:34
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Nov 06, 2024, 08:17
Closure of Trading Window
Oct 30, 2024, 16:01
Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Second Quarter And Half Year Ended September 30, 2024
Oct 30, 2024, 15:57
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Sep 27, 2024, 19:31
Shareholder Meeting / Postal Ballot-Outcome of AGM
Sep 27, 2024, 19:27
U.S. FDA Inspection At The Company''s Facility At Chhatrapati Sambhaji Nagar (Aurangabad), India
Sep 21, 2024, 12:20
U.S. FDA Inspection At The Company''s Facility At Chhatrapati Sambhaji Nagar (Aurangabad), India
Sep 20, 2024, 17:38
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Sep 17, 2024, 16:13
Announcement under Regulation 30 (LODR)-Newspaper Publication
Sep 05, 2024, 15:05
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Sep 04, 2024, 23:20
Intimation Of Book Closure
Sep 03, 2024, 19:48
Business Responsibility and Sustainability Reporting (BRSR)
Sep 03, 2024, 19:42
Reg. 34 (1) Annual Report.
Sep 03, 2024, 19:35
Notice Of 46Th Annual General Meeting Of The Company For F.Y. 2023-24 As Required Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Sep 03, 2024, 19:12

Company Filings to Exchanges

Technical Indicators

RSI(14)
Neutral
50.56
ATR(14)
Less Volatile
49.44
STOCH(9,6)
Overbought
84.11
STOCH RSI(14)
Overbought
98.52
MACD(12,26)
Bullish
13.05
ADX(14)
Strong Trend
27.50
UO(9)
Bearish
66.10
ROC(12)
Uptrend And Accelerating
2.25
WillR(14)
Overbought
-18.23

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Ltd is an Indian research-led global pharmaceutical company founded in 1977. It focuses on developing and manufacturing branded generics, generic drugs, and over-the-counter products in therapeutic areas like respiratory, dermatology, and oncology. The company has a significant presence in emerging markets and operates 14 manufacturing facilities across several countries. Glenmark is involved in drug discovery for new chemical and biological entities, with molecules in various stages of development. It has a strong generics business serving markets like the US and Europe, and an active pharmaceutical ingredients business selling to over 80 countries. The company has made several acquisitions and licensing deals to expand its product portfolio and global reach. Glenmark has launched numerous products across various therapeutic segments and markets, including innovative combinations and first-to-market generics. It has a substantial pipeline of ANDAs filed with the US FDA and continues to receive approvals for new generic products.

Chairperson NameGlenn Saldanha